The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mishugin S.V.

Gorodskaia klinicheskaia bol'nitsa #57 DZ Moskvy

Mordovin A.A.

City Clinical Hospital Fifty-Seven

Ganov V.I.

Altai Territorial Oncology Dispensary

Varlamov S.A.

Altaĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet;
Altaĭskiĭ filial FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Barnaul

Gritskevich A.A.

Vishnevsky Institute of Surgery Ministry of Health of the Russian Federation, Moscow, Russia

Rusakov I.G.

Gorodskaia klinicheskaia bol'nitsa #57 Departamenta zdravookhraneniia Moskvy

Experience with the long-acting somatostatin analogue Octreotide in the treatment of castrate-resistant prostate cancer

Authors:

Mishugin S.V., Mordovin A.A., Ganov V.I., Varlamov S.A., Gritskevich A.A., Rusakov I.G.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2016;5(1): 31‑35

DOI: 10.17116/onkolog20165131-35

Read: 1424 times

Download PDF (RU)
Contact the author
Table of contents

EXPERIENCE WITH THE LONG-ACTING SOMATOSTATIN ANALOGUE OCTREOTIDE IN THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER
EXPERIENCE WITH THE LONG-ACTING SOMATOSTATIN ANALOGUE OCTREOTIDE IN THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER

To cite this article:

Mishugin SV, Mordovin AA, Ganov VI, Varlamov SA, Gritskevich AA, Rusakov IG. Experience with the long-acting somatostatin analogue Octreotide in the treatment of castrate-resistant prostate cancer. P.A. Herzen Journal of Oncology. 2016;5(1):31‑35. (In Russ.)
https://doi.org/10.17116/onkolog20165131-35

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

To treat castration-resistant prostate cancer (CRPC) is one of the most complex problems in urologic oncology. A total of 184 patients with CRPC treated with the long-acting somatostatin analogue octreotide depot have been followed up since 2010. The efficacy and tolerability of the drug at doses of 20 and 30 mg were compared. The 30-mg group showed a high efficiency – a positive response in almost 80% of the patients. The larger dose of the agent caused no additional adverse reactions. The administration of the long-acting somatostatin analogue gives rise to an objective effect, allowing the initiation of chemotherapy and other expensive treatments for CRPC to be postponed.

Keywords:

castration-refractory prostate cancer
androgen deprivation therapy
somatostatin analogues

Authors:

Mishugin S.V.

Gorodskaia klinicheskaia bol'nitsa #57 DZ Moskvy

Mordovin A.A.

City Clinical Hospital Fifty-Seven

Ganov V.I.

Altai Territorial Oncology Dispensary

Varlamov S.A.

Altaĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet;
Altaĭskiĭ filial FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Barnaul

Gritskevich A.A.

Vishnevsky Institute of Surgery Ministry of Health of the Russian Federation, Moscow, Russia

Rusakov I.G.

Gorodskaia klinicheskaia bol'nitsa #57 Departamenta zdravookhraneniia Moskvy

Close metadata

References:

  1. Zlokachestvennye novoobrazovaniya v Rossii v 2014 godu (zabolevaemost' i smertnost'). Pod red. Kaprina A.D., Starinskogo V.V., Petrovoi G.V. M.: MNIOI im. P.A. Gertsena — filial FGBU «NMIRTs» Minzdrava Rossii; 2016.
  2. Matveev B.P., Bukharkin B.V., Matveev V.B. Rak predstatel'noi zhelezy. M.; 1999.
  3. Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schrö­derFH, Sternberg CN, Studer UE. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol. 2012;61(1):11-25. doi:10.1016/j.eururo.2011.08.026.
  4. Abrahamson Per-Anders. Revolutions in the management of hormone-refractory prostate cancer. Eur Urol. 2003;Suppl.2:1-2. doi:10.1016/s1569-9056(02)00201-4.
  5. Crawford ED, Rosenblum M, Ziada AM, Lange PH. Hormone-refractory prostate cancer. Urology. 1999;54(6A, Suppl.):1-7.
  6. Garin A.M. Dotsetaksel (Taksoter) v praktike lecheniya zlokachestvennykh opukholei. M.; 2003:88-94.
  7. Klinicheskaya onkourologiya. Pod red. Matveeva B.P. M.: Izdatel'skii dom «ABV-press»; 2011:723-779.
  8. Kish JA, Bukkapatnam R, Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control. 2001;8(6):487-495.
  9. Rusakov I.G., Gritskevich A.A. Vozmozhnosti analogov somatostatina v lechenii kastratsionno-rezistentnogo raka predstatel'noi zhelezy. Onkologiya. Zhurnal im. P.A. Gertsena. 2012;1(1):73-76.
  10. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki  D, Tao Y, Kelsen D. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72(1):244-248. doi:10.1002/1097-0142(19930701)72:1%3c244::aid-cncr­2820720143%3e3.0.co;2-q.
  11. Mitsiades CS, Mitsiades NS, McMullan CJ. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5(3):221-230. doi:10.1016/s1535-6108(04)00050-9.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.